No Data
BeiGene Canada Announces Inaugural Grant Recipients at New Brunswick's Health Research Symposium
Global Companies With at Least 50% U.S. Revenue Exposure as Trump Eyes Tariffs: BofA
How do foreign investors adjust their positions in Chinese stocks? Alibaba and jd.com frequently appear, while Buffett builds a position that boosts a Hong Kong stock.
① The 13F quarterly reports for US stocks have been released. How are Wall Street institutions adjusting their positions on Chinese stocks? ② Buffett's investment in domino's is boosting a Hong Kong stock. What are the highlights?
China Data Point to Gradual Improvement, but Tariff Risk Looms
bocom intl: Raised beigene's target price to 159 Hong Kong dollars, with product sales and operation continuing to improve in Q3.
Bocom Intl released a research report stating that it has raised the target price of Beigene (06160) to 159 Hong Kong dollars, based on the 3Q performance and the continued strong trend in product sales volume, raising the revenue forecast for 2024-26 by 6-7%. At the same time, the peak sales forecast for Zejula is raised by 4% to 5.4 billion. The bank stated that in the next 12 months, they will focus on: 1) approval of more indications such as LESC, LGC, etc. for Tislelizumab in core developed countries like Europe and America, data readouts of I/O combination therapy (Tislelizumab in combination with OX40, LAG3, etc.); 2) Bcl-2 inhibitors.
【Brokerage Focus】bocom intl raised the target price for beigene (06160), stating that product sales and operation continue to improve in Q3 2024.
Jingu News | bocom intl issued research reports, pointing out that Beigene(06160) 3Q24 total revenue increased by 28.2% year-on-year to 1.002 billion (USD, the same below), including product revenue of 0.993 billion (+66.9% year-on-year), mainly including: 1) Global sales of Zejula amounting to 0.69 billion (MOM +8.3%/YOY +93.0%), with USA accounting for 0.504 billion (MOM -12.2%/YOY +62.3%), the main reason for the slowdown in MOM growth rate is the seasonal fluctuations brought by 3Q holidays in Europe and America, coupled with the high base effect caused by the one-time drug purchase of 15 million at the end of 2Q. 2
No Data
No Data
